Amos heads the Biomarker Group responsible for developing and executing biomarker strategies to support clinical development across the portfolio. This is pursued through research aimed at understanding both drug mechanism of action as well as disease pathophysiology.
Prior to Calico, Amos worked at Genentech leading translational medicine and biomarker development in the areas of cardio‐metabolism, antimicrobial, ophthalmology and wound healing. Prior to that, he championed preclinical research that led to the discovery of etelcalcetide, now an approved drug for secondary hyperparathyroidism (SHPT) at KAI Pharmaceuticals. Amos pursued his postdoctoral studies at the University of California at San Francisco and The Scripps Research Institute, La Jolla, developing small molecule activity-based probes to study enzymes in their natural biological environment.
- Postdoc, University of California at San Francisco and The Scripps Research Institute
- Ph.D. in Molecular Biology Tumor Antigens in Breast Cancer, Tel-Aviv University
- B.Sc. in Biology, Tel-Aviv University